Drug Discovery Featured Articles & Applications

31. 3 Recommendations For Improved AI/ML Models In Drug Discovery 11/28/2022

    AI adoption for drug discovery is projected for 30% growth. However, AI/ML models can be complex. Here are recommendations for keeping your AI actionable, transparent, and repeatable to optimize your drug discovery efforts.

32. Biology Meets Computer Science For Next-Gen Biologics Drug Discovery 11/15/2022

    We have entered a new age in biologics development, which is undergoing a technological revolution with an increasing focus on software-dependent and data-driven results. Integrating the biological and the computational creates a need for specialists working together in parallel.

33. How Can Nanomedicine Innovations Combat Cancer? 10/24/2022

    For the past two decades, nanotechnology has promised a revolution in medicine, especially in creating new ways to deliver medicines to treat cancer. This article shares an overview of nanomedicine and some of the key innovations within the field during the past year.

34. Patenting Treatments Involving Schedule I Substances 10/17/2022

    While schedule 1 drugs remain illegal under federal law, several states and local municipalities have passed laws decriminalizing their use. Your company will want to obtain patent protection for any novel therapeutic uses or treatments you discover. This article discusses how the U.S. Patent and Trademark Office is handling applications involving these substances and covers examples of patents allowed.

35. Search For Similarity: Regulatory Considerations Of Drug Abuse Potential Investigations 10/14/2022

    This article focuses on FDA and EMA regulatory guidelines surrounding drug abuse/dependence and abuse potential investigations, particularly in animal studies. Discussion includes penetration of the blood-brain barrier, structural similarity screening, and investigation of pharmacological similarity.

36. FDA User Fee Programs Reauthorized: FDA’s CBER Is A Clear Winner 10/6/2022

    Last minute, squeaky clean! After years of planning, negotiation, and input, the user fee reauthorization bill was passed and signed into law on the very date that the programs were scheduled to sunset. This article sums up the key takeaways, CBER's reorganization with new product-specific offices, and more.

37. 6 Drug Discovery Learnings From The Lab 10/5/2022

    With more than 25 years of experience, this author shares insights from the perspective of bench science that pertain to experimental design and data generation. These concepts apply not only to individual experiments but also more broadly.

38. Is Phage Therapy Ushering In A Post-Antibiotic Era? 10/3/2022

    Faced with the emergence of resistant bacteria, phage therapy, which uses bacterial viruses (bacteriophages) to treat bacterial infections, is emerging as one of the most credible alternatives to antibiotics.

39. 6 Best Practices For Biopharma Talent Management In 2023 9/23/2022

    The Great Resignation. Inflation and the rising cost of goods and services are compelling workers in a variety of industries to seek higher salaries. This is being acutely felt in the life sciences industry. We need to revolutionize how we're approaching talent management in pharma and biopharma in order to succeed in this environment.

40. Collaborating With Academia For Drug Discovery Targeting Immune-Mediated Diseases 9/16/2022

    Last year, Janssen Biotech and the University of Oxford established a collaboration to understand pathogenic pathways driving immune-mediated inflammatory diseases. They have been creating a cellular map of expressed genes and proteins. This article shares what the collaboration has accomplished so far.